Susan Currie obtained her PhD in Biochemistry (cellular signalling and molecular pharmacology) from the University of Glasgow in 1992 then spent two years at Lilly Research Laboratories, USA, where she studied the role of phospholipase A_² in mast cell activation. She returned to the University of Glasgow in 1994 to join the then newly formed Clinical Research Initiative in heart disease and became a founder member of the school of cardiovascular studies in Glasgow. During this time she progressed from postdoctoral researcher to Principal Investigator examining the role of Calcium/calmodulin protein kinase ll (CaMKll) in cardiac hypertrophy and heart failure. She moved to the University of Strathclyde in 2005 as a Lecturer in Physiology & Pharmacology and established an independent cardiovascular signalling research group with principal interests in CaMKll modulation of cardiac calcium handling and cardiac inflammation. Dr Currie is currently a Reader/Associate Professor within Strathclyde Institute of Pharmacy & Biomedical Sciences and CaMKll as a therapeutic target in cardiac disease remains a key focus of research. More recent research interests include cardiotoxicity in the context of safety pharmacology and devices as well as altered cardiovascular function in ageing.

Dr Currie is currently research group leader for the Cellular Basis of Disease research group within Strathclyde Institute of Pharmacy & Biomedical Sciences. Externally she is chair of the Scottish Cardiovascular Forum (since 2011), is on the committee for the British Society of Cardiovascular Research and is a Fellow of the Physiological Society. Fellowship was awarded in 2017 in recognition of her contribution to cardiovascular research and the discipline of Physiology. She currently teaches on a wide range of classes across both the MPharm and Biomedical Sciences programmes at the University of Strathclyde and coordinates classes on the MPharm programme. She was awarded Fellowship of the Higher Education Academy in 2008.

Dr Currie previously directed the collaborative MPharm programme between the University of Strathclyde and the International Medical University (IMU) in Kuala Lumpur (2012-2017), acting as MPharm representative on the internationalisation committee and was Deputy Director of the MPharm programme at the University of Strathclyde (2012-2018). She is currently Director of Equality, Diversity and Inclusion within Strathclyde Institute of Pharmacy & Biomedical Sciences.